Skip to main content
. 2004 Oct;42(10):4769–4775. doi: 10.1128/JCM.42.10.4769-4775.2004

TABLE 3.

Antimicrobial susceptibility profiles of ESBL-producing isolates of the family Enterobacteriaceae from fecal samples and associated resistance patterns

Yr and isolate ESBL MIC (μg/ml)a
Resistance phenotype
AMC PIP P/T FOX CTX CTX-C CAZ CAZ-C CPM ATM IMP
1991
    Ec13 TEM-4 ≤4/2 >64 ≤16/4 ≤2 >8 ≤0.12/4 4 ≤0.12/4 16 8 ≤0.5
    Ec14 TEM-4 8/4 >64 32/4 4 >8 ≤0.12/4 16 ≤0.12/4 8 8 ≤0.5 St Sp Gm Tb Net Nm Nal Cip Tet Sul Tp
    Ec15 TEM-4 8/4 >64 ≤16/4 ≤2 >8 ≤0.12/4 16 ≤0.12/4 32 16 ≤0.5 St Gm Tb Nal Cip Tet Sul
    Ec16 CTX-M-10 8/4 >64 ≤16/4 ≤2 >8 ≤0.12/4 2 ≤0.12/4 32 64 ≤0.5
    Kp30 CTX-M-10 8/4 >64 ≤16/4 ≤2 >8 ≤0.12/4 8 ≤0.12/4 >32 >64 ≤0.5
    CF CTX-M-10 8/4 >64 ≤16/4 >16 >8 ≤0.12/4 8 ≤0.12/4 32 64 ≤0.5
2003
    Fec 231 TEM-4 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 16 ≤0.12/4 32 8 ≤0.5
    Fec 355 TEM-4 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 8 ≤0.12/4 8 16 ≤0.5 St
    Fec 295 TEM-52 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 32 ≤0.12/4 >32 8 ≤0.5 St Nal Tet Sul Tp Clo
    Fec 394 SHV-2 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 8 ≤0.12/4 32 16 ≤0.5 Tet Sul Tp Clo
    Fec 284Z SHV-12 ≤4/2 >64 ≤16/4 ≤2 128 ≤0.12/4 128 ≤0.12/4 32 64 ≤0.5 Tet Sul Clo
    Fec 335 SHV-12 ≤4/2 >64 ≤16/4 ≤2 64 ≤0.12/4 64 ≤0.12/4 32 32 ≤0.5 Sul Clo
    Fec 222 SHV-12 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 >128 ≤0.12/4 32 ≤0.5
    Fec 250 SHV-12 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 >128 ≤0.12/4 >32 64 ≤0.5 Nal Sul Clo
    Fec 251 SHV-12 ≤4/2 >64 ≤16/4 4 128 ≤0.12/4 128 ≤0.12/4 32 64 ≤0.5 Nal Sul Clo
    Fec 310 SHV-12 ≤4/2 >64 ≤16/4 4 128 ≤0.12/4 128 ≤0.12/4 32 32 ≤0.5 Nal Cip Tet Sul Clo
    Fec 340 SHV-12 ≤4/2 >64 ≤16/4 ≤2 128 ≤0.12/4 128 ≤0.12/4 32 64 ≤0.5 St Nal Cip Tet Sul Tp
    Fec 147 CTX-M-10 8/4 >64 ≤16/4 4 >128 ≤0.12/4 2 ≤0.12/4 >32 >64 ≤0.5 St Sp Nal Sul Tp
    Fec 284X CTX-M-9 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 1 ≤0.12/4 >32 >64 ≤0.5 Nal
    Fec 395 CTX-M-9 ≤4/2 >64 ≤16/4 4 128 ≤0.12/4 4 ≤0.12/4 >32 >64 ≤0.5 St Tet Sul
    Fec 5 CTX-M-9 ≤4/2 >64 ≤16/4 ≤2 >128 ≤0.12/4 1 ≤0.12/4 >32 32 ≤0.5 St Sp Tet Sul Tp
    Fec 87 CTX-M-9 ≤4/2 >64 ≤16/4 8 >128 ≤0.12/4 1 ≤0.12/4 >32 64 ≤0.5 St Sp Nal Cip Tet Sul Tp
    Fec 311 CTX-M-9 8/4 >64 ≤16/4 4 >128 ≤0.12/4 1 ≤0.12/4 >32 >64 ≤0.5 St Sp Tet Sul Tp
    Fec 386 CTX-M-9 ≤4/2 >64 ≤16/4 ≤2 >128 ≤0.12/4 ≤0.5 ≤0.12/4 >32 4 ≤0.5 St Sp Nal Cip Tet Sul Tp
    Fec 325 CTX-M-14 ≤4/2 >64 ≤16/4 ≤2 128 ≤0.12/4 ≤0.5 ≤0.12/4 32 2 ≤0.5 St Nal Tet Sul Tp
    Fec 327 CTX-M-14 ≤4/2 >64 ≤16/4 4 128 ≤0.12/4 1 ≤0.12/4 16 4 ≤0.5 St Nal Cip Tet Sul Tp Clo
    Fec 397 CTX-M-14 ≤4/2 >64 ≤16/4 ≤2 >128 ≤0.12/4 1 ≤0.12/4 >32 32 ≤0.5 Nal
    Fec 166 CTX-M-14 ≤4/2 >64 ≤16/4 ≤2 >128 ≤0.12/4 ≤0.5 ≤0.12/4 8 4 ≤0.5 Nal Tet Sul
    Fec 216 CTX-M-14 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 ≤0.5 ≤0.12/4 >32 4 ≤0.5 St Sp Nm Km Nal Cip Tet Sul Tp
    Fec 245 CTX-M-14 8/4 >64 ≤16/4 4 >128 ≤0.12/4 2 0.25/4 >32 8 ≤0.5 St Tet
    Fec 268 CTX-M-14 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 2 ≤0.12/4 >32 >64 ≤0.5 St Tet
    Fec 336 CTX-M-14 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 1 ≤0.12/4 >32 >64 ≤0.5 Nal Cip Tet Sul Tp Clo
    Fec 383 CTX-M-14 ≤4/2 >64 ≤16/4 ≤2 >128 ≤0.12/4 2 ≤0.12/4 >32 >64 ≤0.5 St Nm Sul Tp
    Fec 38 Unknown >16/8 >64 >64/4 8 128 4/4 1 0.25/4 >32 ≤0.5 ≤0.5 St Sp Tet Sul Tp Clo
2003, healthy volunteers
    VS 27 CTX-M-2 like ≤4/2 >64 ≤16/4 ≤2 >128 ≤0.12/4 8 ≤0.12/4 >32 >64 ≤0.5 Nal Cip Tet Sul
    VS 41 SHV-12 ≤4/2 >64 ≤16/4 ≤2 >128 ≤0.12/4 >128 ≤0.12/4 >32 >64 ≤0.5
    VS 85 SHV-12 ≤4/2 >64 ≤16/4 ≤2 128 ≤0.12/4 128 ≤0.12/4 32 32 ≤0.5 Tet Sul
    VS 62 CTX-M-14 ≤4/2 >64 ≤16/4 4 >128 ≤0.12/4 2 ≤0.12/4 >32 >64 ≤0.5 St Tet Sul Tp
a

AMC, amoxicillin-clavulanate; PIP, piperacillin; P/T, piperacillin-tazobactam; CTX, cefotaxime; CTX-C, cefotaxime-clavulanate; CAZ, ceftazidime; CAZ-C, ceftazidime-clavulanate; CPM, cefepime; ATM, aztreonam; IMP, imipenem.